Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma

키워드

참고문헌 (149)

1. Llovet JM, "Hepatocellular carcinoma", Nat Rev Dis Primers, 7, pp.6~ (2021)
2. Young Eun Chon, "Hepatocellular carcinoma statistics in South Korea", Clinical and Molecular Hepatology, 27(3), pp.512~514 (2021), 대한간학회[DOI]
3. Won Sohn, "Obesity and the risk of primary liver cancer: A systematic review and meta-analysis", Clinical and Molecular Hepatology, 27(1), pp.157~174 (2021), 대한간학회[DOI]
4. Sadahisa Ogasawara, "Switching to systemic therapy after locoregional treatment failure: Definition and best timing", Clinical and Molecular Hepatology, 26(2), pp.155~162 (2020), 대한간학회[DOI]
5. Galle PR, "Patientreported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma(IMbrave150) : an open-label, randomised, phase 3trial", Lancet Oncol, 22, pp.991~1001 (2021)
6. Finn RS, "Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma", N Engl J Med, 382, pp.1894~1905 (2020)
7. Hilmi M, "Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma : current knowledge and future research directions", J Immunother Cancer, 7, pp.333~ (2019)
8. Kudo M, "CheckMate 040 cohort 5 : a phase I", II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis, 2021, pp.75, 600~609
9. El-Khoueiry AB, "Nivolumab in patients with advanced hepatocellular carcinoma(CheckMate 040) : an open-label, non-comparative, phase 1", 2 dose escalation and expansion trial, 2017, pp.389, 2492~2502
10. Sangro B, "Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma", J Hepatol, 73, pp.1460~1469 (2020)
11. Zhou Dexi, "Tumor-Associated Macrophages in Hepatocellular Carcinoma: Friend or Foe?", Gut and Liver, 15(4), pp.500~516 (2021), 거트앤리버 소화기연관학회협의회[DOI]
12. Park DJ, "Preferential expression of programmed death ligand 1 protein in tumor-associated macrophages and its potential role in immunotherapy for hepatocellular carcinoma", Int J Mol Sci, 22, pp.4710~ (2021)
13. Thorsson V, "The immune landscape of cancer", Immunity, 48, pp.812~830 (2018)
14. Cancer Genome Atlas Research Network, "Comprehensive and integrative genomic characterization of hepatocellular carcinoma", Cell, 169, pp.1327~1341 (2017)
15. Zhang Q, "Landscape and dynamics of single immune cells in hepatocellular carcinoma", Cell, 179, pp.829~845 (2019)
16. Sun Y, "Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma", Cell, 184, pp.404~421 (2021)
17. Ho DW, "Single-cell RNA sequencing shows the immunosuppressive landscape and tumor heterogeneity of HBV-associated hepatocellular carcinoma", Nat Commun, 12, pp.3684~ (2021)
18. Wang X, "TOX promotes the exhaustion of antitumor CD8+ T cells by preventing PD1 degradation in hepatocellular carcinoma", J Hepatol, 71, pp.731~741 (2019)
19. Siddiqui I, "Intratumoral Tcf1+PD-1+CD8+ T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy", Immunity, 50, pp.195~211 (2019)
20. Sung PS, "Immunological mechanisms for hepatocellular carcinoma risk after direct-acting antiviral treatment of hepatitis C virus infection", J Clin Med, 10, pp.221~ (2021)
21. Kim HD, "association between expression level of PD1 by tumor-infiltrating CD8+ T cells and features of hepatocellular carcinoma", Gastroenterology, 155, pp.1936~1950 (2018)
22. Kurebayashi Y, "Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification", Hepatology, 68, pp.1025~1041 (2018)
23. Zhang Q, "Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas", Gut, 68, pp.2019~2031 (2019)
24. Wu C, "Myeloid signature reveals immune contexture and predicts the prognosis of hepatocellular carcinoma", J Clin Invest, 130, pp.4679~4693 (2020)
25. Nguyen PHD, "Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinoma", Nat Commun, 12, pp.227~ (2021)
26. Sung PS, "Realworld outcomes of nivolumab in patients with unresectable hepatocellular carcinoma in an endemic area of hepatitis B virus infection", Front Oncol, 10, pp.1043~ (2020)
27. Yang H, "Heterogenous responses to nivolumab in a single metastatic nodule in hepatocellular carcinoma : role of salvage surgery", Hepatobiliary Surg Nutr, 8, pp.569~571 (2019)
28. Cheng AL, "Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma", J Hepatol, 72, pp.307~319 (2020)
29. Gomez Perdiguero E, "Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors", Nature, 518, pp.547~551 (2015)
30. Tacke F, "Macrophage heterogeneity in liver injury and fibrosis", J Hepatol, 60, pp.1090~1096 (2014)
31. Scott CL, "Bone marrow-derived monocytes give rise to selfrenewing and fully differentiated Kupffer cells", Nat Commun, 7, pp.10321~ (2016)
32. Beattie L, "Bone marrow-derived and resident liver macrophages display unique transcriptomic signatures but similar biological functions", J Hepatol, 65, pp.758~768 (2016)
33. Huang Y, "The role of tumor associated macrophages in hepatocellular carcinoma", J Cancer, 12, pp.1284~1294 (2021)
34. Su Jong Yu, "Deciphering and Reversing Immunosuppressive Cells in the Treatment of Hepatocellular Carcinoma", Journal of Liver Cancer, 20(1), pp.1~16 (2020), 대한간암학회[DOI]
35. Ruf B, "Immunobiology and immunotherapy of HCC : spotlight on innate and innate-like immune cells", Cell Mol Immunol, 18, pp.112~127 (2021)
36. Zhou J, "Tumor-associated macrophages : recent insights and therapies", Front Oncol, 10, pp.188~ (2020)
37. Heymann F, "Liver inflammation abrogates immunological tolerance induced by Kupffer cells", Hepatology, 62, pp.279~291 (2015)
38. Mossanen JC, "Chemokine(C-C motif)receptor 2-positive monocytes aggravate the early phase of acetaminophen-induced acute liver injury", Hepatology, 64, pp.1667~1682 (2016)
39. Malehmir M, "Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer", Nat Med, 25, pp.641~655 (2019)
40. Diggs LP, "The effects of platelet accumulation in fatty liver disease", Nat Rev Gastroenterol Hepatol, 16, pp.393~394 (2019)
41. Remmerie A, "Osteopontin expression identifies a subset of recruited macrophages distinct from kupffer cells in the fatty liver", Immunity, 53, pp.641~657 (2020)
42. Kazankov K, "The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis", Nat Rev Gastroenterol Hepatol, 16, pp.145~159 (2019)
43. Carpino G, "Increased liver localization of lipopolysaccharides in human and experimental NAFLD", Hepatology, 72, pp.470~485 (2020)
44. Esparza-Baquer A, "TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms", Gut, 70, pp.1345~1361 (2021)
45. Ramachandran P, "Resolving the fibrotic niche of human liver cirrhosis at single-cell level", Nature, 575, pp.512~518 (2019)
46. Mulder K, "Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease", Immunity, 54, pp.1883~1900 (2021)
47. Sheng J, "Topological analysis of hepatocellular carcinoma tumour microenvironment based on imaging mass cytometry reveals cellular neighbourhood regulated reversely by macrophages with different ontogeny", Gut, 71, pp.1176~1191 (2022)
48. Yao W, "A natural CCR2antagonist relieves tumor-associated macrophage-mediated immunosuppression to produce a therapeutic effect for liver cancer", EBioMedicine, 22, pp.58~67 (2017)
49. Li X, "Targeting of tumourinfiltrating macrophages via CCL2", CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma, 2017, pp.66, 157~167
50. Teng KY, "Blocking the CCL2-CCR2 axis using CCL2-neutralizing antibody is an effective therapy for hepatocellular cancer in a mouse model", Mol Cancer Ther, 16, pp.312~322 (2017)
51. Avila MA, "Targeting CCL2", CCR2 in tumor-infiltrating macrophages : a tool emerging out of the box against hepatocellular carcinoma, 2019, pp.7, 293~294
52. Noy R, "Tumor-associated macrophages : from mechanisms to therapy", Immunity, 41, pp.49~61 (2014)
53. Wu J, "M2 macrophagederived exosomes facilitate HCC metastasis by transferring αM β2 integrin to tumor cells", Hepatology, 73, pp.1365~1380 (2021)
54. Song G, "Global immune characterization of HBV", HCV-related hepatocellular carcinoma identifies macrophage and T-cell subsets associated with disease progression, 2020, pp.6, 90~
55. Chen DP, "Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma", J Hepatol, 71, pp.333~343 (2019)
56. Chen DP, "Peritumoral monocytes induce cancer cell autophagy to facilitate the progression of human hepatocellular carcinoma", Autophagy, 14, pp.1335~1346 (2018)
57. 성필수, "Infiltration of T Cells and Programmed Cell Death Ligand 1-expressing Macrophages as a Potential Predictor of Lenvatinib Response in Hepatocellular Carcinoma", Journal of Liver Cancer, 20(2), pp.128~134 (2020), 대한간암학회[DOI]
58. Lu LC, "Increased expression of programmed death-ligand 1 in infiltrating immune cells in hepatocellular carcinoma tissues after sorafenib treatment", Liver Cancer, 8, pp.110~120 (2019)
59. Park DJ, "EpCAM-high liver cancer stem cells resist natural killer cellmediated cytotoxicity by upregulating CEACAM1", J Immunother Cancer, 8, pp.e000301~ (2020)
60. Lee TK, "CD24+liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation", Cell Stem Cell, 9, pp.50~63 (2011)
61. Barkal AA, "CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy", Nature, 572, pp.392~396 (2019)
62. Logtenberg MEW, "The CD47-SIRPα immune checkpoint", Immunity, 52, pp.742~752 (2020)
63. Chen J, "Macrophages induce CD47 upregulation via IL-6 and correlate with poor survival in hepatocellular carcinoma patients", Oncoimmunology, 8, pp.e1652540~ (2019)
64. Weiskopf K, "CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer", J Clin Invest, 126, pp.2610~2620 (2016)
65. Xiao Z, "Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma", Cancer Lett, 360, pp.302~309 (2015)
66. Lo J, "Anti-CD47antibody suppresses tumour growth and augments the effect of chemotherapy treatment in hepatocellular carcinoma", Liver Int, 36, pp.737~745 (2016)
67. Tang KH, "CD133+ liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin", interleukin-8, Hepatology, pp.2012, 55[DOI]
68. Xiao P, "Neurotensin", IL-8 pathway orchestrates local inflammatory response and tumor invasion by inducing M2 polarization of tumor-associated macrophages and epithelial-mesenchymal transition of hepatocellular carcinoma cells, 2018, pp.7, e1440166~
69. Lee TK, "Cancer stem cells in hepatocellular carcinoma-from origin to clinical implications", Nat Rev Gastroenterol Hepatol, 19, pp.26~44 (2022)
70. Yin Z, "IL-6", STAT3 pathway intermediates M1, J Cell Biochem, pp.2018, 119[DOI]
71. Wan S, "Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells", Gastroenterology, 147, pp.1393~1404 (2014)
72. Chen Y, "TNF-α derived from M2 tumor-associated macrophages promotes epithelialmesenchymal transition and cancer stemness through the Wnt", β-catenin pathway in SMMC-7721 hepatocellular carcinoma cells, 2019, pp.378, 41~50
73. Zhang J, "Hypoxiainducible factor-1α", interleukin-1β signaling enhances hepatoma epithelial-mesenchymal transition through macrophages in a hypoxic-inflammatory microenvironment, 2018, pp.67, 1872~1889
74. Fu XT, "Macrophage-secreted IL-8 induces epithelial-mesenchymal transition in hepatocellular carcinoma cells by activating the JAK2", STAT3, Int J Oncol, pp.2015, 46[DOI]
75. Zhong CQ, "FABP4 suppresses proliferation and invasion of hepatocellular carcinoma cells and predicts a poor prognosis for hepatocellular carcinoma", Cancer Med, 7, pp.2629~2640 (2018)
76. Fan QM, "Tumor-associated macrophages promote cancer stem cell-like properties via transforming growth factor-beta1-induced epithelialmesenchymal transition in hepatocellular carcinoma", Cancer Lett, 352, pp.160~168 (2014)
77. Xue ST, "The role of the key autophagy kinase ULK1 in hepatocellular carcinoma and its validation as a treatment target", Autophagy, 16, pp.1823~1837 (2020)
78. Fu XT, "Tumorassociated macrophages modulate resistance to oxaliplatin via inducing autophagy in hepatocellular carcinoma", Cancer Cell Int, 19, pp.71~ (2019)
79. Guo B, "M2 tumorassociated macrophages produce interleukin-17 to suppress oxaliplatin-induced apoptosis in hepatocellular carcinoma", Oncotarget, 8, pp.44465~44476 (2017)
80. Sun K, "Autophagydeficient Kupffer cells promote tumorigenesis by enhancing mtROS-NF-κB-IL1α", β-dependent inflammation and fibrosis during the preneoplastic stage of hepatocarcinogenesis, 2017, pp.388, 198~207
81. Deust A, "Macrophage autophagy protects against hepatocellular carcinogenesis in mice", Sci Rep, 11, pp.18809~ (2021)
82. Liu LZ, "CCL15recruits suppressive monocytes to facilitate immune escape and disease progression in hepatocellular carcinoma", Hepatology, 69, pp.143~159 (2019)
83. He Q, "IL-1β-induced elevation of solute carrier family 7 member 11 promotes hepatocellular carcinoma metastasis through up-regulating programmed death ligand 1 and colony-stimulating factor 1", Hepatology, 74, pp.3174~3193 (2021)
84. Ke M, "MicroRNA-148b-colony-stimulating factor-1 signaling-induced tumor-associated macrophage infiltration promotes hepatocellular carcinoma metastasis", Biomed Pharmacother, 120, pp.109523~ (2019)
85. Chai ZT, "MicroRNA-26a suppresses recruitment of macrophages by downregulating macrophage colony-stimulating factor expression through the PI3K", Akt pathway in hepatocellular carcinoma, 2015, pp.8, 56~
86. Ao JY, "Colony-stimulating factor 1 receptor blockade inhibits tumor growth by altering the polarization of tumor-associated macrophages in hepatocellular carcinoma", Mol Cancer Ther, 16, pp.1544~1554 (2017)
87. Zhu Y, "Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade", Gut, 68, pp.1653~1666 (2019)
88. Wang Y, "MiR-125a", b inhibits tumor-associated macrophages mediated in cancer stem cells of hepatocellular carcinoma by targeting CD90, 2019, pp.120, 3046~3055
89. Liu J, "Endoplasmic reticulum stress causes liver cancer cells to release exosomal miR-23a-3p and up-regulate programmed death ligand 1 expression in macrophages", Hepatology, 70, pp.241~258 (2019)
90. Yin C, "SALL4-mediated upregulation of exosomal miR-146a-5p drives T-cell exhaustion by M2 tumor-associated macrophages in HCC", Oncoimmunology, 8, pp.1601479~ (2019)
91. Sung PS, "Natural killer cell dysfunction in hepatocellular carcinoma : pathogenesis and clinical implications", Int J Mol Sci, 19, pp.3648~ (2018)
92. Wu Y, "Monocyte", macrophage-elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48, Hepatology, pp.2013, 57[DOI]
93. Ma PF, "Cytotherapy with M1-polarized macrophages ameliorates liver fibrosis by modulating immune microenvironment in mice", J Hepatol, 67, pp.770~779 (2017)
94. Kuang DM, "Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1", J Exp Med, 206, pp.1327~1337 (2009)
95. Wu K, "Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1", programmed death-1 interactions, 2009, pp.69, 8067~8075
96. Ma J, "PD1Hi CD8+ T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma", J Immunother Cancer, 7, pp.331~ (2019)
97. Petty AJ, "Hedgehog-induced PD-L1 on tumor-associated macrophages is critical for suppression of tumor-infiltrating CD8+ T cell function", JCI Insight, 6, pp.e146707~ (2021)
98. Chamseddine AN, "Modulating tumorassociated macrophages to enhance the efficacy of immune checkpoint inhibitors : a TAM-pting approach", Pharmacol Ther, 231, pp.107986~ (2022)
99. Chen CL, "Arginine signaling and cancer metabolism", Cancers(Basel), 13, pp.3541~ (2021)
100. Pan Y, "Tumor-associated macrophages in tumor immunity", Front Immunol, 11, pp.583084~ (2020)
101. Geiger R, "L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity", Cell, 167, pp.829~842 (2016)
102. Kaneda MM, "PI3Kγ is a molecular switch that controls immune suppression", Nature, 539, pp.437~442 (2016)
103. De Henau O, "Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells", Nature, 539, pp.443~447 (2016)
104. Sung PS, "Roles of unphosphorylated ISGF3 in HCV infection and interferon responsiveness", Proc Natl Acad Sci U S A, 112, pp.10443~10448 (2015)
105. Sung PS, "Interferon response in hepatitis C virusinfected hepatocytes : issues to consider in the era of directacting antivirals", Int J Mol Sci, 21, pp.2583~ (2020)
106. Lund Laursen T, "Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology", Scand J Gastroenterol, 53, pp.986~993 (2018)
107. Bolte FJ, "Intra-hepatic depletion of mucosal-associated invariant T cells in hepatitis c virus-induced liver inflammation", Gastroenterology, 153, pp.1392~1403 (2017)
108. Carlin AF, "Temporal dynamics of inflammatory cytokines", chemokines during sofosbuvir and ribavirin therapy for genotype 2 and 3 hepatitis C infection, 2015, pp.62, 1047~1058
109. Spaan M, "Immunological analysis during interferon-free therapy for chronic hepatitis C virus infection reveals modulation of the natural killer cell compartment", J Infect Dis, 213, pp.216~223 (2016)
110. Xiang X, "Targeting tumor-associated macrophages to synergize tumor immunotherapy", Signal Transduct Target Ther, 6, pp.75~ (2021)
111. Yu S, "Tumor-infiltrating immune cells in hepatocellular carcinoma : Tregs is correlated with poor overall survival", PLoS One, 15, pp.e0231003~ (2020)
112. Wu Q, "Blocking triggering receptor expressed on myeloid cells-1-positive tumor-associated macrophages induced by hypoxia reverses immunosuppression and anti-programmed cell death ligand 1resistance in liver cancer", Hepatology, 70, pp.198~214 (2019)
113. Liu C, "Treg cells promote the SREBP1-dependent metabolic fitness of tumor-promoting macrophages via repression of CD8+ T cellderived interferon-γ", Immunity, 51, pp.381~397 (2019)
114. Ringelhan M, "The immunology of hepatocellular carcinoma", Nat Immunol, 19, pp.222~232 (2018)
115. Chen MM, "Polarization of tissue-resident TFH-like cells in human hepatoma bridges innate monocyte inflammation and M2b macrophage polarization", Cancer Discov, 6, pp.1182~1195 (2016)
116. Shalapour S, "Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity", Nature, 551, pp.340~345 (2017)
117. Sung PS, "Inflammationinduced IgA plus tumor-associated macrophages express PDL1and causes impaired T cell functionality in hepatocellular carcinoma", Hepatology, 72, pp.780A~781A (2022)
118. Arvanitakis K, "Tumor-associated neutrophils in hepatocellular carcinoma pathogenesis, prognosis, and therapy", Cancers(Basel), 13, pp.2899~ (2021)
119. Peng ZP, "Glycolytic activation of monocytes regulates the accumulation and function of neutrophils in human hepatocellular carcinoma", J Hepatol, 73, pp.906~917 (2020)
120. Zhou SL, "Tumor-associated neutrophils recruit macrophages and Tregulatory cells to promote progression of hepatocellular carcinoma and resistance to sorafenib", Gastroenterology, 150, pp.1646~1658 (2016)
121. Zhou SL, "Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma", Hepatology, 56, pp.2242~2254 (2012)
122. Singh P, "The immune modulation effect of locoregional therapies and its potential synergy with immunotherapy in hepatocellular carcinoma", J Hepatocell Carcinoma, 7, pp.11~17 (2020)
123. Chew V, "Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma", Gut, 68, pp.335~346 (2019)
124. Kang BY, "Phenylboronic acid conjugated to doxorubicin for the treatment of hepatocellular carcinoma through transcatheter arterial chemoembolization", Research Square web stie (2021)[DOI]
125. Chung YH, "Diffusion-weighted MRI and 18F-FDG PET correlation with immunity in early radiotherapy response in BNL hepatocellular carcinoma mouse model : timeline validation", Eur J Nucl Med Mol Imaging, 46, pp.1733~1744 (2019)
126. Jeong KY, "Combination of macrophage inflammatory protein 1 alpha with existing therapies to enhance the antitumor effects on murine hepatoma", J Radiat Res, 56, pp.37~45 (2015)
127. Choi C, "Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma", World J Gastroenterol, 25, pp.2416~2429 (2019)
128. Gyu Sang Yoo, "Radiation-induced abscopal effect and its enhancement by programmed cell death 1 blockade in the hepatocellular carcinoma: A murine model study", Clinical and Molecular Hepatology, 27(1), pp.144~156 (2021), 대한간학회[DOI]
129. Kim HJ, "Clinical significance of soluble programmed cell death ligand-1(sPD-L1)in hepatocellular carcinoma patients treated with radiotherapy", Radiother Oncol, 129, pp.130~135 (2018)
130. Kudo M, "Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma : a randomised phase 3non-inferiority trial", Lancet, 391, pp.1163~1173 (2018)
131. Lee J, "Comparative analysis of lenvatinib and hepatic arterial infusion chemotherapy in unresectable hepatocellular carcinoma : a multi-center, propensity score study", J Clin Med, 10, pp.4045~ (2021)
132. Lee J, "A realworld comparative analysis of lenvatinib and sorafenib as a salvage therapy for transarterial treatments in unresectable HCC", J Clin Med, 9, pp.4121~ (2020)
133. Kimura T, "Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model", Cancer Sci, 109, pp.3993~4002 (2018)
134. Yi C, "Lenvatinib targets FGF receptor 4 to enhance antitumor immune response of anti–programmed cell death-1 in HCC", Hepatology, 74, pp.2544~2560 (2021)
135. Dong N, "M2 macrophages mediate sorafenib resistance by secreting HGF in a feed-forward manner in hepatocellular carcinoma", Br J Cancer, 121, pp.22~33 (2019)
136. Chen Y, "CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice", Hepatology, 61, pp.1591~1602 (2015)
137. Chen Y, "Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha", C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice, 2014, pp.59, 1435~1447
138. Ou DL, "Regorafenib enhances antitumor immunity via inhibition of p38 kinase", Creb1, J Immunother Cancer, pp.2021, 9[DOI]
139. Granito A, "Regorafenib combined with other systemic therapies : exploring promising therapeutic combinations in HCC", J Hepatocell Carcinoma, 8, pp.477~492 (2021)
140. Shang R, "Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma", Gut, 70, pp.1746~1757 (2021)
141. Ma L, "Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma", J Hepatol, 75, pp.1397~1408 (2021)
142. Lin C, "Tumour-associated macrophages-derived CXCL8 determines immune evasion through autonomous PD-L1 expression in gastric cancer", Gut, 68, pp.1764~1773 (2019)
143. Zong Z, "M1 macrophages induce PD-L1 expression in hepatocellular carcinoma cells through IL-1β signaling", Front Immunol, 10, pp.1643~ (2019)
144. Jansen CS, "An intra-tumoral niche maintains and differentiates stem-like CD8 T cells", Nature, 576, pp.465~470 (2019)
145. Yan W, "Tim-3 fosters HCC development by enhancing TGF-β-mediated alternative activation of macrophages", Gut, 64, pp.1593~1604 (2015)
146. Li J, "Co-inhibitory molecule B7 superfamily member 1 expressed by tumor-infiltrating myeloid cells induces dysfunction of anti-tumor CD8+ T cells", Immunity, 48, pp.773~786 (2018)
147. Li G, "Nanoliposome C6-ceramide increases the anti-tumor immune response and slows growth of liver tumors in mice", Gastroenterology, 154, pp.1024~1036 (2018)
148. Wang B, "Transition of tumor-associated macrophages from MHC class II(hi)to MHC class II(low)mediates tumor progression in mice", BMC Immunol, 12, pp.43~ (2011)
149. Zhou DY, "Zoledronic acid inhibits infiltration of tumor-associated macrophages and angiogenesis following transcatheter arterial chemoembolization in rat hepatocellular carcinoma models", Oncol Lett, 14, pp.4078~4084 (2017)

관련 논문AI추천